Press

Educational activity

Latest Evidence to Support Macrolide Use for the Treatment of Hospitalized Patients
With Community-Acquired Pneumonia

giamarellos-bourboulis_evangelos_j-09-12-2024

Evangelos J. Giamarellos-Bourboulis, MD, PhD, FISAC

Professor of Internal Medicine and Infectious Diseases
Director MSc Program of Infectious Diseases
National and Kapodistrian University of Athens, Greece
President, European Sepsis Alliance, Berlin, Germany

Michael S. Niederman, MD, MACP, FCCM, FCCP

Lauder Family Professor of Pulmonary and Critical Care Medicine
Weill Cornell Medical College New York
New York, United States

Microbiome Playlist

What is microbiome?

Professor Evangelos Giamarellos-Bourboulis explains what is Microbiome.

Watch on Youtube

Microbiome and antibiotics

Are antibiotics useful? Professor Evangelos Giamarellos-Bourboulis explains their impact on Microbiome.

Watch on Youtube

Antibiotic resistance

What is antibiotic resistance? Professor Evangelos Giamarellos-Bourboulis explains how this affects us.

Watch on Youtube

Limit antibiotics side effects

How can we limit side effects of antibiotics on microbiome?
Check out PROGRESS

Watch on Youtube

Interferon-gamma driven elevation of CXCL9: a new sepsis endotype independently associated with mortality

hiss2024-10-25T09:53:56+03:00October 25th, 2024|

25September, 2024

HEPARIN-BINDING PROTEIN LEVELS PREDICT UNFAVORABLE OUTCOME IN COVID-19 PNEUMONIA: A POST HOC ANALYSIS OF THE SAVE TRIAL

hiss2024-10-18T12:27:27+03:00September 25th, 2024|

23September, 2024

Modulation of Metabolomic Profile in Sepsis According to the State of Immune Activation

hiss2024-10-18T11:34:04+03:00September 23rd, 2024|

17September, 2024

Clinical Phenotyping for Prognosis and Immunotherapy Guidance in Bacterial Sepsis and COVID-19

hiss2024-10-18T11:44:36+03:00September 17th, 2024|

14March, 2024

Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial

hiss2024-03-14T14:03:07+03:00March 14th, 2024|

7February, 2024

qSOFA combined with suPAR for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial

hiss2024-02-07T15:45:40+03:00February 7th, 2024|

2February, 2024

Developing a Tool for Differentiation Between Bacterial and Viral Respiratory Infections Using Myxovirus Resistance Protein A and C-Reactive Protein

hiss2024-02-02T13:03:15+03:00February 2nd, 2024|

5January, 2024

Association of Vitamin D with Severity and Outcome of COVID-19: Clinical and Experimental Evidence

hiss2024-01-05T14:33:18+03:00January 5th, 2024|

33rd European Congress of Clinical Microbiology & Infectious Diseases

A personalized immunotherapeutic approach to the treatment of sepsis: Evangelos Giamarellos, ECCMID 2023

The symposia ‘Sepsis – Biomarker-driven immunotherapy: it works.‘ (Symposia number: SY137) was presented at ECCMID 2023, 15-18 April, 2023, Copenhagen, Denmark.

Click here to watch the interview

6th Annual Meeting of the European Sepsis Alliance

Watch on Youtube

Interview with Prof. Evangelos Giamarellos-Bourboulis for the Phase 3 SAVE-MORE Study

Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Interview with the Evangelos Giamarellos-Bourboulis for the Phase 3 SAVE-MORE Study
Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Watch the interview

Press conference of the results of the SAVE-MORE trial

“Press conference of the results of SAVE-MORE trial” ERT Interview, September 2021

Watch the interview

Educational activity

Latest Evidence to Support Macrolide Use for the Treatment of Hospitalized Patients
With Community-Acquired Pneumonia

Evangelos J. Giamarellos-Bourboulis, MD, PhD, FISAC

Michael S. Niederman, MD, MACP, FCCM, FCCP

Microbiome Playlist

What is microbiome?

Microbiome and antibiotics

Antibiotic resistance

Limit antibiotics side effects

Recent Posts

Interferon-gamma driven elevation of CXCL9: a new sepsis endotype independently associated with mortality

HEPARIN-BINDING PROTEIN LEVELS PREDICT UNFAVORABLE OUTCOME IN COVID-19 PNEUMONIA: A POST HOC ANALYSIS OF THE SAVE TRIAL

Modulation of Metabolomic Profile in Sepsis According to the State of Immune Activation

Clinical Phenotyping for Prognosis and Immunotherapy Guidance in Bacterial Sepsis and COVID-19

Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial

qSOFA combined with suPAR for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial

Developing a Tool for Differentiation Between Bacterial and Viral Respiratory Infections Using Myxovirus Resistance Protein A and C-Reactive Protein

Association of Vitamin D with Severity and Outcome of COVID-19: Clinical and Experimental Evidence

Presentations & Interviews

33rd European Congress of Clinical Microbiology & Infectious Diseases

6th Annual Meeting of the European Sepsis Alliance

Interview with Prof. Evangelos Giamarellos-Bourboulis for the Phase 3 SAVE-MORE Study

Interview with the Evangelos Giamarellos-Bourboulis for the Phase 3 SAVE-MORE Study

Press conference of the results of the SAVE-MORE trial